ABL2 and lung carcinoma: A significant reduction in colony formation was observed in both the H1915 (homozygous for R351W mutation) and H2110 (heterozygous for the G340L mutation) lung cancer cell lines, whereas the control cell lines and cell lines carrying ABL2 mutations (H650 and H1623) displayed no change in colony formation when treated with imatinib (Fig 1A).